CV Sciences, Inc. to Announce First Quarter 2025 Results on May 14, 2025
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1718204&tp_key=5ae745f8b7. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, May 21, 2025, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13753631.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
[email protected]
SOURCE: CV Sciences, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
MetLife (MET) To Report Earnings Tomorrow: Here Is What To Expect
Global insurance giant MetLife (NYSE:MET) will be reporting results this Wednesday afternoon. Here's what investors should know. MetLife beat analysts' revenue expectations by 3% last quarter, reporting revenues of $18.83 billion, up 10.6% year on year. It was a slower quarter for the company, with a significant miss of analysts' book value per share estimates and a miss of analysts' EPS estimates. Is MetLife a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting MetLife's revenue to be flat year on year at $18.64 billion, in line with its flat revenue from the same quarter last year. Adjusted earnings are expected to come in at $2.16 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. MetLife has missed Wall Street's revenue estimates four times over the last two years. Looking at MetLife's peers in the life insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Corebridge Financial delivered year-on-year revenue growth of 5.8%, beating analysts' expectations by 7.3%, and Lincoln Financial Group reported revenues up 4.4%, topping estimates by 1.1%. Lincoln Financial Group traded up 7.8% following the results. Read our full analysis of Corebridge Financial's results here and Lincoln Financial Group's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the life insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.9% on average over the last month. MetLife is down 5.3% during the same time and is heading into earnings with an average analyst price target of $94.14 (compared to the current share price of $75). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
6 minutes ago
- Yahoo
HubSpot (HUBS) Reports Q2: Everything You Need To Know Ahead Of Earnings
Sales and marketing software maker HubSpot (NYSE:HUBS) will be announcing earnings results this Wednesday afternoon. Here's what to look for. HubSpot beat analysts' revenue expectations by 2% last quarter, reporting revenues of $714.1 million, up 15.7% year on year. It was a strong quarter for the company, with an impressive beat of analysts' billings estimates and a solid beat of analysts' EBITDA estimates. It added 10,319 customers to reach a total of 258,258. Is HubSpot a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting HubSpot's revenue to grow 16% year on year to $739.3 million, slowing from the 20.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. HubSpot has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 3.1% on average. Looking at HubSpot's peers in the sales and marketing software segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Freshworks delivered year-on-year revenue growth of 17.5%, beating analysts' expectations by 2.9%, and BigCommerce reported revenues up 3.2%, topping estimates by 1.3%. Freshworks traded down 2.5% following the results while BigCommerce was up 4.6%. Read our full analysis of Freshworks's results here and BigCommerce's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the sales and marketing software stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3% on average over the last month. HubSpot is down 7.8% during the same time and is heading into earnings with an average analyst price target of $736.74 (compared to the current share price of $512.20). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Primerica Earnings: What To Look For From PRI
Financial services company Primerica (NYSE:PRI) will be reporting results this Wednesday after market hours. Here's what to expect. Primerica beat analysts' revenue expectations by 2.1% last quarter, reporting revenues of $803.6 million, up 9.4% year on year. It was a mixed quarter for the company, with net premiums earned in line with analysts' estimates but a slight miss of analysts' book value per share estimates. Is Primerica a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Primerica's revenue to grow 6.1% year on year to $786.1 million, slowing from the 9.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.20 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Primerica has missed Wall Street's revenue estimates four times over the last two years. Looking at Primerica's peers in the life insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Corebridge Financial delivered year-on-year revenue growth of 5.8%, beating analysts' expectations by 7.3%, and Lincoln Financial Group reported revenues up 4.4%, topping estimates by 1.1%. Lincoln Financial Group traded up 7.8% following the results. Read our full analysis of Corebridge Financial's results here and Lincoln Financial Group's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the life insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.9% on average over the last month. Primerica is down 2.8% during the same time and is heading into earnings with an average analyst price target of $307.29 (compared to the current share price of $265.39). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
